Answers are grounded in this paper and cite their sources.
Laboratory assessment shows pathogen-free platelets for transfusion in patients, highlighting a potential alternative to donor systems.
circulation of platelet products. Initial implementation will likely focus on high-value applications, such as transfusion for alloimmunized patients, before broader adoption. The long-term goal is to replace the vulnerable donor-dependent system with on-demand production of standardized, pathogen-free, and universally compatible platelets.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: